Loading...
•
Jun 30, 2022
Cassava Sciences Q2 2022 Earnings Report
Announced financial results for the second quarter ended June 30, 2022, a mid-year corporate update, and interim clinical results of an open-label study with simufilam.
Key Takeaways
Cassava Sciences reported a net loss of $19.3 million for the second quarter of 2022, with cash and cash equivalents totaling $197.2 million as of June 30, 2022. A total of over 400 patients are now enrolled in the Phase 3 program of simufilam in Alzheimer’s disease.
Over 400 patients are now enrolled in the Phase 3 program of simufilam in Alzheimer’s disease.
An open-label extension study for the Phase 3 program is expected to be initiated in the second half of 2022.
Top-line clinical results for the open-label study are expected to be announced approximately year-end 2022.
Patient enrollment for the CMS is expected to be completed in Q4 2022, with clinical results anticipated in Q3 2023.